Smaller doses of GLP-1 RAs may not benefit those with severe metabolic dysfunction or those needing substantial weight loss
Leah Joseph explains the differences in dosing schedules, effectiveness, side effect profiles, and administration methods to help patients choose the option that fits their needs best
EClinicalMedicine 55
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
Acknowledgements This work was partially supported by grants from JSPS (KAKENHI Grant Numbers JP21K08032 and 24K11270) to KS
"A young man escalated his dose of retatrutide, he experienced secretory diarrhoea, which was very severe, and he was admitted to hospital requiring a lot of intravenous fluid rehydration," Dr Holt said
